Figure 4.
![Figure 4. Immunization with DCs pulsed with 12B1-derived CRCL provides significant protection to 12B1 tumor challenge. DCs were incubated with 50 μg/mL 12B1-derived CRCL or the same concentration of purified HSP70 or unfractionated lysate protein for 24 hours. DCs (5 × 105) were injected subcutaneously into the groin on days - 14 and - 7, and the mice were challenged with 12B1 cells (103) in the opposite groin on day 0 (saline versus DC, not significant [ns]; DC versus DC + lysate, ns; DC versus DC + HSP70, P < .05; DC versus DC + CRCL, P < .0001; DC + HSP70 versus DC + CRCL, P < .005; pooled data from 2 experiments, n = 12-16 mice per group).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/101/11/10.1182_blood-2002-10-3108/5/h81134417004.jpeg?Expires=1722711225&Signature=NbByuOj7Mjpqu7hxpCJ43423DX2g8kQC1tuVlLmVP0bEvZeIWJymwd8w~Jr21CmxKOghzig4fledU1C9B~wUlKf60bTsy8AOuvdCs6mUAn17HSU5~AKgj7hcdyr7BVdeCK5eTB1Ya2NoTRvCCK2ybFZtzJtw-SPh3TrdeTJhcz4d79wp8FVDDvzVrKB~1u2AgqgbAUefD5YiJyarCf8lmX7r-6ReNf07uvzQVoyxjWDHKi~Id~8b6vGzI0y3gLLZUeHVRXkQtq5vt4Lloq23IvELPnBb25gfyWL2jPr3gbjn3uiOoRFnRmKsggZfktYgVtThwAQ4YiylAMA7JdDRIg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Immunization with DCs pulsed with 12B1-derived CRCL provides significant protection to 12B1 tumor challenge. DCs were incubated with 50 μg/mL 12B1-derived CRCL or the same concentration of purified HSP70 or unfractionated lysate protein for 24 hours. DCs (5 × 105) were injected subcutaneously into the groin on days - 14 and - 7, and the mice were challenged with 12B1 cells (103) in the opposite groin on day 0 (saline versus DC, not significant [ns]; DC versus DC + lysate, ns; DC versus DC + HSP70, P < .05; DC versus DC + CRCL, P < .0001; DC + HSP70 versus DC + CRCL, P < .005; pooled data from 2 experiments, n = 12-16 mice per group).
